- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01910129
Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy
A Randomized, Multi-center, Double-blind, Parallel, Crossover Study of a Non-invasive Neurostimulation to the Vagus Nerve With the gammaCore Device for the Reduction in Frequency of Seizures Associated With Epilepsy.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Southern Neurology
-
Sydney, New South Wales, Australia, 2067
- Strategic Health Evaluators
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is diagnosed with epilepsy with; primary generalized tonic-clonic or partial complex or simple complex or focal onset seizures, with or without secondary generalization.
- The patient's present antiepileptic drug (AED) therapy is ineffective or intolerable
- The patient is receiving a stable dose of up to 2 oral AED medication(s) and is not expected to have any change in his/her baseline AED treatment during the treatment period.
- The patient is having more than 2 recordable seizures a month.
Exclusion Criteria:
- The patient has had status epilepticus within the last six months.
- The patient has had epilepsy surgery or a VNS implant.
- The patient has had a history or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted).
- The patient has had 4 weeks continuous seizure freedom last 2 months.
- The patient has psychogenic non-epileptic seizures (PNES) seizures.
- The patient has a concomitant progressive CNS disease including progressive myoclonus epilepsy.
- The patient has a significant history of cardiac, renal, neurologic (other than epilepsy), psychiatric, oncologic, endocrinologic, metabolic, or hepatic disease, which would adversely affect their participation in this study.
- The patient has had an episode of status epilepticus within 4 weeks of Screening.
10. Has a lesion (including lymphadenopathy), dysaesthesia, previous surgery or abnormal anatomy at the GammaCore treatment site.
11. Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction.
12. Has an abnormal baseline ECG (e.g. second and third degree heart block, atrial fibrillation, atrial flutter, recent history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction).
13. Has had a previous bilateral, right, or left cervical vagotomy. 14. Has uncontrolled high blood pressure. 15. Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
16. Has a history of carotid endarterectomy or vascular neck surgery on the right side.
17. Has been implanted with metal cervical spine hardware or has a metallic implant near the GammaCore stimulation site.
18. Has a recent or repeated history of syncope. 19. Has a known history or suspicion of substance abuse or addiction. 20. In the opinion of the investigator/research staff the subject is incapable of operating the GammaCore device as intended and performing the data collection procedures.
21. Is pregnant, nursing, thinking of becoming pregnant in the next 9 months, or of childbearing years and is unwilling to use an accepted form of birth control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: gammaCore
Active stimulation treatment
|
vagal verve stimulation 3 times a day 8 hours apart
|
PLACEBO_COMPARATOR: sham gammaCore
Inactive stimulation treatment
|
vagal verve stimulation 3 times a day 8 hours apart
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Seizures
Time Frame: 16 weeks
|
The seizure frequency was collected in the subject diary throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Seizure
Time Frame: 16 weeks
|
Duration of seizure was recorded by the subject in the subject diary throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
|
16 weeks
|
Severity of Seizure
Time Frame: 16 weeks
|
The Seizure Severity Questionnaire (SSQ) is a self-reported assessment tool, which categorizes seizures into three phases: warning, ictal activity and postictal recovery. The recovery phase is subdivided into three components (cognitive, emotional and physical aspects of recovery), each of which is rated for frequency, severity and bothersome. Overall assessment of seizure severity is measured with the last two items. Items are positively scored from a scale of 1-7, with lower scores representing a better status. 1 = none, never or mild and 7 = extremely frequent, severe or high. The severity was reported for seizures occuring throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks). |
16 weeks
|
Type of Adverse Events
Time Frame: 16 weeks
|
Type of adverse events were split in to Adverse Events, Adverse Device Effects and Serious Adverse Events. Adverse events were reported throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks). For frequency see the Adverse Event Table. |
16 weeks
|
Number of Seizure Free Days
Time Frame: 16 weeks
|
The number of seizure-free days was collected from the subjects' diary.
The total number of days observed days for each phase and the total number of seizure free days for each phase are presented for the course of the study throughout Intervention 1/Phase 2 (8 weeks) and Intervention 2/Phase 3 (8 weeks).
|
16 weeks
|
Quality of Life in Epilepsy
Time Frame: 16 weeks
|
The Quality of Life in Epilepsy-31 (QOLIE-31) instrument is a self- administered questionnaire. It includes seven subscales: Overall Quality of Life, Seizure Worry, Emotional Well-Being, Energy/Fatigue, Cognitive, Medication Effects, and Social Function. Questions 1-30 can yield seven individual scores (per subtest) and a total (composite) score. Higher scores indicate better QOL with values ranging from 1 to 100. Question 31 is a subjective assessment of one's general health condition.Higher scores indicate a better-reported general health condition with the range being 1-10. Scores are presented at end of Intervention 1/Phase 2 (8 weeks) and at the end of Intervention 2/Phase 3 (8 weeks). |
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roy Beran, Professor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E-AU-01
- 173/2013 (OTHER: clinical trail notification)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seizure
-
Children's Hospital of Fudan UniversityRecruitingSeizures | Seizure Disorder | Seizure Newborn | Seizure GeneralizedChina
-
Dartmouth-Hitchcock Medical CenterCompletedDepression | Non-Epileptic Seizure | Psychogenic Non-Epileptic Seizure | Psychogenic SeizureUnited States
-
SK Life Science, Inc.Active, not recruitingPartial Seizure | Focal SeizureChina, Japan, Korea, Republic of
-
Michael A. Gelfand, MD, PhDEpilepsy FoundationCompletedGeneralized Tonic Clonic Seizure | Drug Resistant Epilepsy | Drop Seizures | Complex Partial Seizure | Fall Due to SeizureUnited States
-
Vitaflo International, LtdChildren's Hospital of PhiladelphiaCompletedSeizure DisordersUnited States
-
Brain SentinelUnknownEpilepsy | Non-Epileptic Seizure | Motor SeizureAustria
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedEpilepsy | Seizures | Partial Seizure DisorderUnited States, Australia, France, Belgium, Taiwan, Spain, Argentina, Poland, India, Ukraine, Finland, Korea, Republic of, Russian Federation, Chile, Thailand, Hungary, Israel, New Zealand, Canada, Mexico, Norway, Netherlands, South...
-
University of California, San FranciscoCompleted
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedPsychogenic Non-Epileptic SeizureMexico
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedEpilepsy | Epilepsies, Partial | Partial Seizure Disorder | Complex Partial Seizure DisorderCosta Rica, Peru, El Salvador, Guatemala
Clinical Trials on gammaCore
-
ElectroCore INCCompletedCluster HeadacheUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of Texas Southwestern Medical CenterElectroCore INCWithdrawnPost-Traumatic HeadacheUnited States
-
CentraCareElectroCore INCCompletedTraumatic Brain Injury | Acute Brain InjuriesUnited States
-
ElectroCore INCCompleted
-
ElectroCore INCCompletedMigraine DisordersUnited States
-
ElectroCore INCCompletedMigraineBelgium, Denmark, Germany, Greece, Netherlands, Norway, Spain, United Kingdom
-
ElectroCore INCCompleted
-
Massachusetts General HospitalElectroCore INCRecruitingSubarachnoid Hemorrhage, AneurysmalUnited States
-
Northwell HealthCompletedSubarachnoid Hemorrhage, AneurysmalUnited States